Loading...
How often to perform surveillance testing after curative treatment for patients with stage II–III colorectal cancer (CRC) remains controversial, as guidelines support varying intensity of screening, including follow-up imaging with computed tomography (CT) scan, testing of serum carcinoembryonic antigen (CEA), and colonoscopy.
Investigators now report the results of an international, randomized trial (COLOFOL) that evaluated two surveillance testing strategies following curative surgery for stage II–III CRC. A total of 2365 per-protocol patients (median age, 65) were randomized to high-frequency testing (CT scan of the chest and abdomen and CEA at 6, 12, 18, 24, and 36 months) or low-frequency testing (CT scan and CEA at 12 and 36 months). C…